Guard Therapeutics International AB (GUARD) - Cash Flow Conversion Efficiency

Latest as of September 2025: -1.630x

Based on the latest financial reports, Guard Therapeutics International AB (GUARD) has a cash flow conversion efficiency ratio of -1.630x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-90.70 Million ≈ $-9.76 Million USD) by net assets (Skr55.63 Million ≈ $5.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Guard Therapeutics International AB to measure how much of total assets are equity-financed.

Guard Therapeutics International AB - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Guard Therapeutics International AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does Guard Therapeutics International AB reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Guard Therapeutics International AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guard Therapeutics International AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
CirChem AB ST:CIRCHE	-0.103x
HiteJinro Holdings Co Ltd KO:000145	-0.020x
TOMCO ENERGY POST CON. F:NI41	N/A
Newpeak Metals Ltd AU:NPM	-0.132x
Citrus Plant5-L TA:CTPL5	-0.014x
QMC Quantum Minerals Corp V:QMC	0.001x
BOD Science Ltd AU:BOD	-0.175x
Millennium Food-Tech LP TA:MIFT	N/A

Annual Cash Flow Conversion Efficiency for Guard Therapeutics International AB (2012–2024)

The table below shows the annual cash flow conversion efficiency of Guard Therapeutics International AB from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Guard Therapeutics International AB worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr37.97 Million ≈ $4.09 Million	Skr-94.75 Million ≈ $-10.20 Million	-2.496x	-43.52%
2023-12-31	Skr66.73 Million ≈ $7.18 Million	Skr-116.05 Million ≈ $-12.49 Million	-1.739x	-201.96%
2022-12-31	Skr177.36 Million ≈ $19.09 Million	Skr-102.14 Million ≈ $-10.99 Million	-0.576x	-30.46%
2021-12-31	Skr175.78 Million ≈ $18.92 Million	Skr-77.59 Million ≈ $-8.35 Million	-0.441x	+7.34%
2020-12-31	Skr79.69 Million ≈ $8.58 Million	Skr-37.96 Million ≈ $-4.09 Million	-0.476x	+58.36%
2019-12-31	Skr52.62 Million ≈ $5.66 Million	Skr-60.21 Million ≈ $-6.48 Million	-1.144x	-105.75%
2018-12-31	Skr-2.94 Million ≈ $-316.28K	Skr-58.46 Million ≈ $-6.29 Million	19.890x	+1063.17%
2017-12-31	Skr31.96 Million ≈ $3.44 Million	Skr-66.01 Million ≈ $-7.10 Million	-2.065x	-33.35%
2016-12-31	Skr30.34 Million ≈ $3.26 Million	Skr-46.98 Million ≈ $-5.06 Million	-1.549x	-123.61%
2015-12-31	Skr42.69 Million ≈ $4.59 Million	Skr-29.56 Million ≈ $-3.18 Million	-0.693x	-427.08%
2014-12-31	Skr52.25 Million ≈ $5.62 Million	Skr-6.87 Million ≈ $-738.89K	-0.131x	-18.18%
2013-12-31	Skr25.42 Million ≈ $2.74 Million	Skr-2.83 Million ≈ $-304.12K	-0.111x	-134.81%
2012-12-31	Skr30.58 Million ≈ $3.29 Million	Skr-1.45 Million ≈ $-155.83K	-0.047x	--

About Guard Therapeutics International AB

ST:GUARD Sweden Biotechnology

Market Cap

$3.02 Million

Skr28.03 Million SEK

Market Cap Rank

#29436 Global

#669 in Sweden

Share Price

Skr1.39

Change (1 day)

-10.78%

52-Week Range

Skr0.95 - Skr25.90

All Time High

Skr3260.75